| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
V37586-5mg |
≥97% | ￥850.00 |
货期：3-5天 | - | - | - | - |
|
V37586-10mg |
≥97% | ￥1560.00 |
货期：3-5天 | - | - | - | - |
|
V37586-25mg |
≥97% | ￥3500.00 |
货期：3-5天 | - | - | - | - |
|
V37586-50mg |
≥97% | ￥5600.00 |
货期：3-5天 | - | - | - | - |
|
| 靶点： | RdRp, RSV,SARS-CoV-2, HCV, COVID-19, LCMV. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 体内研究： | EIDD-2749 (0.2, 1, 5 mg/kg; p.o.; single daily for 4 days) shows good orally efficacious in RSV infection mice model in a dose-dependent manner. EIDD-2749 shows high efficacious to SARS-CoV-2 infection and is effective with a single daily dose versus molnupiravir administered twice daily in vivo. |
||||||||||||||||||||
| 参考文献： | 1. Sourimant J, et al. 4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. Science. 2022 Jan 14;375(6577):161-167. 2. Abas AH, et al. 4’-fluorouridine and its derivatives as potential COVID-19 oral drugs: a review [version 1; peer review: 1 approved with reservations, 1 not approved]. F1000Research 2022, 11:410. 3. George R. Painter, et al. 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. Patent WO2019173602A1. |
||||||||||||||||||||
| 保存条件： | -20°C | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京